German biotech startup Catalym secures €50M to develop immunotherapy for most cancers sufferers

Picture credit score: CataLYm Bayern-based Catalayam, a biotechnology firm growing immunotherapies for most cancers sufferers, introduced on Tuesday, 22 November that it has secured €50M in a Collection C spherical of funding. The spherical was co-led by new traders Brandon Capital and Zito Capital, with participation from present traders Forbion, Novartis Enterprise Fund, Vesalius BioCapital … Read more